Rare Disease Report

Janet Woodcock - Duchenne Drug Review and the Patients' Input

NOVEMBER 02, 2016
Janet Woodcock, MD



Janet Woodcock, MD,  Director of the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) talks about the important role that the Duchenne advocacy groups played in the FDA's review of eteplirsen.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.